Nonsteroidal Anti-inflammatory Drugs
Studies suggest that brain inflammation may play a role in Alzheimer’s disease damage, and that nonsteroidal anti-inflammatory drugs (NSAIDs) could potentially slow the progression of the disease. However, human clinical trials have not shown that these medications are beneficial. For example, in patients who already have Alzheimer’s, naproxen (Aleve) and rofecoxib (Vioxx) did not delay disease progression. Another clinical trail was examining whether celecoxib (Celebrex) and naproxen could prevent Alzheimer’s disease in older healthy people at risk for this disease. The trial was stopped because the data indicated an apparent increase in cardiovascular and cerebrovascular events among the participants taking naproxen when compared with those on placebo. This step was taken as a precautionary measure to ensure the safety of the study’s participants. Researchers are continuing to explore the role of other anti-inflammatory drugs in the treatment or prevention of Alzheimer’s disease.
A thoughtful evaluation must be performed by a physician before taking any medications, over-the-counter drugs, supplements, or herbs. The American Health Assistance Foundation does not endorse any of these medications, vitamins, or herbs. A qualified physician should make an informed decision based on each person's medical history and current prescriptions. The medication summaries provided do not include all of the information important for patient use and should not be used as a substitute for professional medical advice. The prescribing physician should be consulted concerning any questions that you have.
The information provided in this section of our website was obtained from the National Institute on Aging.
Reviewed on 2/14/2007